Clinical efficacy and immune response of BCL-2 inhibitors combined with hypomethylating agents in the treatment of acute myeloid leukemia
The combination of BCL-2 inhibitors and HMAs had good efficacy and safety in AML patients who were unfit for high-dose chemotherapy, which may improve the immune microenvironment and enhance anti-leukemia immune response.
Authors
- Jianing Yu (ORCID: https://orcid.org/0000-0001-5425-3271)
- Xiaohuan Peng (ORCID: https://orcid.org/0000-0002-4655-0003)
- Futian Tang (ORCID: https://orcid.org/0000-0001-9495-7695)
- Yanhong Li (ORCID: https://orcid.org/0009-0007-8361-3310)
- Liansheng Zhang (ORCID: https://orcid.org/0000-0001-6444-6421)
- Jun Bai
- Lijuan Li (ORCID: https://orcid.org/0009-0001-6375-1245)
Institutions
- Lanzhou University Second Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1007/s12672-024-01348-8
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- Lanzhou University
- National Natural Science Foundation of China
- Natural Science Foundation of Gansu Province
- Fundamental Research Funds for the Central Universities